Fuji Pharma Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange (TSE), mainly engaged in manufacturing and selling prescription pharmaceuticals.

Since our establishment in 1965, Fuji has promoted the corporate philosophy: "We help people lead healthy lives by offering excellent pharmaceuticals." and "Our corporate growth is proportional to our personal growth."

Fuji Pharma has been actively engaged in fields that are considered to have high barriers to entry, such as the production of hormone drugs with difficult manufacturing control and injectable drugs with strict quality control standards. These challenges have formed our foundation, and we have grown as a specialty pharmaceutical company pursuing the fields of women's healthcare, acute medical care, and biosimilars.

The expansion of insurance coverage for infertility treatment in April 2022 added new indications and dosages for 13 ingredients and 19 products by March 2023, of which we have the largest lineup of additional approved products in Japan. With the expansion of insurance coverage, the overall infertility treatment market is expanding, benefitting companies in the segment including Fuji Pharma. We are determined to continue our mission as a specialty pharmaceutical company to help find solution for unmet medical needs in women's health and achieve greater well-being so that all women can feel physically, mentally and socially fulfilled.